SCHEMBL3038583

SCHEMBL3038583

CCCNCC.CO[SiH2]OC

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
CYP2C19 P33261 2/20 0.39
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP1A2 P05177 1/20 0.38
TP53 P04637 1/20 0.35
KDM1A O60341 5/20 0.32
ADH1B P00325 1/20 0.31
ADH1A P07327 1/20 0.31
ADH7 P40394 1/20 0.31
SAT1 P21673 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11139003 0.85 TSHR (0.67) TSHRCYP2C19MEN1GLAKMT2A
Diethylamine SCHEMBL27841769 0.83 TP53 (0.53) TSHRCYP2C19MEN1GLAKMT2A
SCHEMBL975756 0.80 CYP2C19 (0.42) TSHRCYP2C19MEN1GLAKMT2A
SCHEMBL7885 0.80
Bromide SCHEMBL25346344 0.76
Hydrochloric Acid SCHEMBL6260885 0.76
SCHEMBL21065744 0.76
Ammonia Solution, Strong SCHEMBL11366235 0.76
Ammonia Solution, Strong SCHEMBL10410334 0.76
SCHEMBL10904114 0.76 CYP2C19 (0.62) TSHRCYP2C19MEN1GLAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190637-A1 Curing Catalyst MERCK PATENT GESELLSCHAFT (DE) 2010-07-29 US claimed
CN-110366580-B Method of forming encapsulated pigment slurries for waterborne topcoat coating compositions 巴斯夫涂料有限公司 2021-08-06 CN disclosed
CN-107207885-B Method of forming passivated pigment slurries for waterborne topcoat coating compositions 巴斯夫涂料有限公司 2020-03-03 CN disclosed
US-8586659-B2 Redispersible surfaced-modified particles MERCK PATENT GMBH (DE) 2013-11-19 US disclosed
US-20100215959-A1 SILANES MERCK PATENT GMBH (DE) 2010-08-26 US disclosed
US-20100190637-A1 Curing Catalyst MERCK PATENT GESELLSCHAFT (DE) 2010-07-29 US disclosed
US-20100092761-A1 NANOPARTICLES MERCK PATENT GESELLSCHAFT (DE) 2010-04-15 US disclosed
US-20100010137-A1 REDISPERSIBLE SURFACED-MODIFIED PARTICLES MERCK PATENT GESELLSCHAFT (DE) 2010-01-14 US disclosed
US-20080248289-A1 Zinc Oxide Nanoparticles MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100215959-A1 SILANES SGMS1, SGMS2, SUMO3 TSHR 3867/4885CYP2C19 3256/4885MEN1 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.